Dorrin Zarrin Khat1,2, Mansoor Husain3,4,5,6,7,8. 1. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada. 2. Toronto General Hospital Research Institute, University Health Network, Toronto, Canada. 3. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada. mansoor.husain@uhn.ca. 4. Department of Medicine, University of Toronto, Toronto, Canada. mansoor.husain@uhn.ca. 5. Toronto General Hospital Research Institute, University Health Network, Toronto, Canada. mansoor.husain@uhn.ca. 6. Heart and Stroke Richard Lewar Centre of Excellence, University of Toronto, Toronto, Canada. mansoor.husain@uhn.ca. 7. Ted Rogers Centre for Heart Research, University Health Network, Toronto, Canada. mansoor.husain@uhn.ca. 8. Peter Munk Cardiac Centre, University Health Network, Toronto, Canada. mansoor.husain@uhn.ca.
Abstract
PURPOSE OF REVIEW: In addition to their effects on glycemic control, two specific classes of relatively new anti-diabetic drugs, namely the sodium glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have demonstrated reduced rates of major adverse cardiovascular events (MACE) in subjects with type 2 diabetes (T2D) at high risk for cardiovascular disease (CVD). This review summarizes recent experimental results that inform putative molecular mechanisms underlying these benefits. RECENT FINDINGS: SGLT2i and GLP-1RA exert cardiovascular effects by targeting in both common and distinctive ways (A) several mediators of macro- and microvascular pathophysiology: namely (A1) inflammation and atherogenesis, (A2) oxidative stress-induced endothelial dysfunction, (A3) vascular smooth muscle cell reactive oxygen species (ROS) production and proliferation, and (A4) thrombosis. These agents also exhibit (B) hemodynamic effects through modulation of (B1) natriuresis/diuresis and (B2) the renin-angiotensin-aldosterone system. This review highlights that while GLP-1RA exert direct effects on vascular (endothelial and smooth muscle) cells, the effects of SGLT2i appear to include the activation of signaling pathways that prevent adverse vascular remodeling. Both SGLT2i and GLP-1RA confer hemodynamic effects that counter adverse cardiac remodeling.
PURPOSE OF REVIEW: In addition to their effects on glycemic control, two specific classes of relatively new anti-diabetic drugs, namely the sodium glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have demonstrated reduced rates of major adverse cardiovascular events (MACE) in subjects with type 2 diabetes (T2D) at high risk for cardiovascular disease (CVD). This review summarizes recent experimental results that inform putative molecular mechanisms underlying these benefits. RECENT FINDINGS: SGLT2i and GLP-1RA exert cardiovascular effects by targeting in both common and distinctive ways (A) several mediators of macro- and microvascular pathophysiology: namely (A1) inflammation and atherogenesis, (A2) oxidative stress-induced endothelial dysfunction, (A3) vascular smooth muscle cell reactive oxygen species (ROS) production and proliferation, and (A4) thrombosis. These agents also exhibit (B) hemodynamic effects through modulation of (B1) natriuresis/diuresis and (B2) the renin-angiotensin-aldosterone system. This review highlights that while GLP-1RA exert direct effects on vascular (endothelial and smooth muscle) cells, the effects of SGLT2i appear to include the activation of signaling pathways that prevent adverse vascular remodeling. Both SGLT2i and GLP-1RA confer hemodynamic effects that counter adverse cardiac remodeling.
Entities:
Keywords:
Cardioprotection; GLP-1RA; Hemodynamics; SGLT2i; Type 2 diabetes; Vascular pathophysiology
Authors: Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz Journal: N Engl J Med Date: 2013-09-02 Impact factor: 91.245
Authors: Hisko Oeseburg; Rudolf A de Boer; Hendrik Buikema; Pim van der Harst; Wiek H van Gilst; Herman H W Silljé Journal: Arterioscler Thromb Vasc Biol Date: 2010-05-06 Impact factor: 8.311
Authors: Sebastian Steven; Matthias Oelze; Alina Hanf; Swenja Kröller-Schön; Fatemeh Kashani; Siyer Roohani; Philipp Welschof; Maximilian Kopp; Ute Gödtel-Armbrust; Ning Xia; Huige Li; Eberhard Schulz; Karl J Lackner; Leszek Wojnowski; Serge P Bottari; Philip Wenzel; Eric Mayoux; Thomas Münzel; Andreas Daiber Journal: Redox Biol Date: 2017-06-22 Impact factor: 11.799
Authors: Alessandra Saldanha de Mattos Matheus; Lucianne Righeti Monteiro Tannus; Roberta Arnoldi Cobas; Catia C Sousa Palma; Carlos Antonio Negrato; Marilia de Brito Gomes Journal: Int J Hypertens Date: 2013-03-04 Impact factor: 2.420
Authors: Mansoor Husain; Stephen C Bain; Ole K Jeppesen; Ildiko Lingvay; Rasmus Sørrig; Marianne B Treppendahl; Tina Vilsbøll Journal: Diabetes Obes Metab Date: 2020-02-05 Impact factor: 6.577